PLXDC2: A Potential Drug Target for Cancer (G84898)

Target Name: PLXDC2

NCBI ID: G84898

PLXDC2

PLXDC2: A Potential Drug Target for Cancer

PLXDC2 (1200007L24Rik) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the PDGF signaling pathway, which is a critical pathway involved in cell growth, differentiation, and survival. PLXDC2 has been shown to play a role in the development and progression of various diseases, including cancer. As a drug target or biomarker, PLXDC2 is of great interest to researchers because of its potential to be used for therapeutic interventions.

PLXDC2 is a 21-kDa transmembrane protein that is expressed in the brain, heart, and kidneys. It is a member of the PDGF signaling pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The PDGF signaling pathway is composed of two main proteins: PDGF-A and PDGF-B. PDGF-A is a 21-kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. PDGF-B is a 24-kDa protein that is also expressed in various tissues of the body.

PLXDC2 is a critical protein that is involved in the development and progression of various diseases, including cancer. For example, PLXDC2 has been shown to play a role in the development of neurofibromatosis, a genetic disorder that is characterized by the formation of tumors. PLXDC2 is also involved in the development of cancer, including melanoma, a type of skin cancer.

In addition to its role in the development of diseases, PLXDC2 is also of interest as a drug target or biomarker because of its potential to be used for therapeutic interventions. For example, PLXDC2 has been shown to be a potential therapeutic target for cancer, including melanoma. Researchers have found that inhibiting PLXDC2 can lead to the regression of human melanoma tumors. Additionally, PLXDC2 has also been shown to be a potential biomarker for cancer, as it has been found to be elevated in the blood and urine of patients with various types of cancer.

PLXDC2 is also of interest as a potential drug target because of its role in the regulation of cell survival. For example, PLXDC2 has been shown to play a role in the regulation of cell survival by promoting the production of DNA repair factors. This means that PLXDC2 can be used to treat diseases where cell survival is being regulated incorrectly, such as cancer.

In conclusion, PLXDC2 is a protein that is expressed in various tissues of the body and is involved in the development and progression of various diseases, including cancer. As a drug target or biomarker, PLXDC2 is of great interest to researchers because of its potential to be used for therapeutic interventions. Further research is needed to fully understand the role of PLXDC2 in diseases and its potential as a drug target or biomarker.

Protein Name: Plexin Domain Containing 2

Functions: May play a role in tumor angiogenesis

The "PLXDC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLXDC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets